

References

1. Alzheimer's Association. 2023 Alzheimer's Disease Facts and Figures. Alzheimer's & Dementia 2023 10. Available at: https://www.alz.org/downloads/Facts_Figures_2023.pdf
2. California Workgroup on Guidelines for Alzheimer's Disease Management, State of California, Department of Public Health. Guideline for Alzheimer's Disease Management. Final report, 2008. Available at: http://www.alz.org/socal/images/professional_GuidelineFullReport.pdf.
3. Alzheimer's Disease Program, Chronic Disease Branch Division for Disease Control and Prevention Services, Texas Department of State Health Services. Clinical best practices for early detection, diagnosis, and pharmaceutical and non-pharmaceutical treatment of persons with Alzheimer's Disease. Publication No 44-14023. February 2013. Available at: <http://dshs.state.tx.us/alzheimers/pdf/Early-Detection-Final.doc>
4. Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses. *Drugs*. 2012 Apr 16;72(6):789-802. doi: 10.2165/11631830-000000000-00000. PMID: 22480339.
5. Scope A, Bhadhuri A, Pennington B. Systematic Review of Cost-Utility Analyses That Have Included Carer and Family Member Health-Related Quality of Life. *Value Health*. 2022 Sep;25(9):1644-1653. doi: 10.1016/j.jval.2022.02.008. Epub 2022 Mar 24. PMID: 35339379.
6. Peña-Longobardo LM, Rodríguez-Sánchez B, Oliva-Moreno J, Aranda-Reneo I, López-Bastida J. How relevant are social costs in economic evaluations? The case of Alzheimer's disease. *Eur J Health Econ*. 2019 Nov;20(8):1207-1236. doi:

10.1007/s10198-019-01087-6. Epub 2019 Jul 24. Erratum in: Eur J Health Econ. 2021 Jul;22(5):849. PMID: 31342208; PMCID: PMC8149344.

7. Fuh JL, Wang SJ. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan. *Int J Geriatr Psychiatry*. 2008 Jan;23(1):73-8. doi: 10.1002/gps.1842. PMID: 17520661.
8. Gagnon M, Rive B, Hux M, Guilhaume C. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. *Can J Psychiatry*. 2007 Aug;52(8):519-26. doi: 10.1177/070674370705200810. PMID: 17955915.
9. Getsios D, Blume S, Ishak KJ, Maclaine GD. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation. *Pharmacoeconomics*. 2010;28(5):411-27. doi: 10.2165/11531870-000000000-00000. PMID: 20402542.
10. López-Bastida J, Hart W, García-Pérez L, Linertová R. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. *J Alzheimers Dis*. 2009;16(2):399-407. doi: 10.3233/JAD-2009-0965. PMID: 19221429
11. Guk-Hee Suh, MD, PhD, Modeling the Cost-Effectiveness of Galantamine for Mild to Moderately Severe Alzheimer's Disease in Korea. *VALUE IN HEALTH*. Volume 12 • Supplement 3 • 2009
12. Teipel SJ, Ewers M, Reisig V, Schweikert B, Hampel H, Happich M. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease. *Eur Arch Psychiatry Clin Neurosci*. 2007 Sep;257(6):330-6. doi: 10.1007/s00406-007-0727-1. Epub 2007 Apr 1. PMID: 17404699.

13. Weycker D, Taneja C, Edelsberg J, Erder MH, Schmitt FA, Setyawan J, Oster G. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. *Curr Med Res Opin.* 2007 May;23(5):1187-97. doi: 10.1185/030079907x188071. PMID: 17519086.
14. Getsios D, Blume S, Ishak KJ, Maclaine G, Hernández L. An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom. *Alzheimers Dement.* 2012 Jan;8(1):22-30. doi: 10.1016/j.jalz.2010.07.001. Epub 2011 Mar 21. PMID: 21420366.
15. Hartz S, Getsios D, Tao S, Blume S, Maclaine G. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation. *BMC Neurol.* 2012 Feb 8;12:2. doi: 10.1186/1471-2377-12-2. PMID: 22316501; PMCID: PMC3296601.
16. Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, Berenbaum PA, Goldman PA, Williams LW, Weinstein MC. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. *Neurology.* 1999 Apr 12;52(6):1138-45. doi: 10.1212/wnl.52.6.1138. PMID: 10214734.
17. Knapp M, King D, Romeo R, Adams J, Baldwin A, Ballard C, Banerjee S, Barber R, Bentham P, Brown RG, Burns A, Dening T, Findlay D, Holmes C, Johnson T, Jones R, Katona C, Lindsay J, Macharouthu A, McKeith I, McShane R, O'Brien JT, Phillips PPJ, Sheehan B, Howard R. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial). *Int J Geriatr Psychiatry.* 2017 Dec;32(12):1205-1216. doi: 10.1002/gps.4583. Epub 2016 Oct 13. PMID: 27739182; PMCID: PMC5724694.
18. Saint-Laurent Thibault C, Özer Stillman I, Chen S, Getsios D, Proskorovsky I, Hernandez L, Dixit S. Cost-utility analysis of memantine extended release added

to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US. *J Med Econ.* 2015;18(11):930-43. doi: 10.3111/13696998.2015.1063501. Epub 2015 Aug 26. PMID: 26086535.

19. Touchon J, Lachaine J, Beauchemin C, Granghaud A, Rive B, Bineau S. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France. *Eur J Health Econ.* 2014 Nov;15(8):791-800. doi: 10.1007/s10198-013-0523-y. Epub 2013 Aug 9. PMID: 23928827; PMCID: PMC4201748.
20. Pfeil AM, Kressig RW, Szucs TD. Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland. *Swiss Med Wkly.* 2012 Nov 21;142:w13676. doi: 10.4414/smw.2012.13676. PMID: 23180021.
21. Rive B, Aarsland D, Grishchenko M, Cochran J, Lamure M, Toumi M. Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway. *Int J Geriatr Psychiatry.* 2012 Jun;27(6):573-82. doi: 10.1002/gps.2755. Epub 2011 Aug 10. PMID: 21834130.
22. Lachaine J, Beauchemin C, Legault M, Bineau S. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. *Can J Psychiatry.* 2011 Oct;56(10):596-604. doi: 10.1177/070674371105601005. PMID: 22014692.
23. Nagy B, Brennan A, Brandtmüller A, Thomas SK, Sullivan SD, Akehurst R. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models. *Int J*

Geriatr Psychiatry. 2011 May;26(5):483-94. doi: 10.1002/gps.2551. Epub 2010 Sep 15. PMID: 20845395.